Thyroid Cancer Clinical Trial
Official title:
The Use of Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Who Are Treated With Radioactive Iodine for Thyroid Cancer
The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |